Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Journal: Future oncology (London, England)
Published: June 13, 2025
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Journal: The New England journal of medicine
Published: February 05, 2025
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.
Journal: Molecular cancer therapeutics
Published: June 12, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: February 23, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Journal: Future oncology (London, England)
Published: February 13, 2024
Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells.
Journal: Frontiers in immunology
Published: August 05, 2021
Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
Journal: American journal of hematology
Published: December 16, 2019
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
Journal: Clinical genitourinary cancer
Published: March 20, 2019
PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.
Journal: American journal of hematology/oncology
Published: September 01, 2016
Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Journal: American journal of hematology
Published: February 16, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026